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Dynamic contrast-enhanced magnetic resonance imaging was performed in control patients with normal bone marrow and patients with
untreated bone metastases of prostate cancer (PCa). Perfusion data were assessed using region of interest-based and pixel-wise current
standard postprocessing techniques (signal intensity pattern, increase in signal intensity, upslope, time to peak, extended Kety model, k-
means clustering). Bone marrow perfusion is significantly increased in bone metastases of PCa compared to normal bone marrow. Pixel-wise
kinetic modeling should be recommended to assess tumoral processes affecting bone marrow microcirculation.
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Current imaging screening for bone metastases of prostate
cancer (PCa) including technetium-99m bone scan, targeted
X-rays, and magnetic resonance imaging (MRI) are not
effective in revealing early tumor changes induced by
anticancer drugs [1–3]. Dynamic contrast-enhanced MRI
(DCE-MRI) is now recognized as a potential early predictor
of response to drug therapy and radiotherapy [4–7]. The
usefulness of the technique in various benign and malignant
musculoskeletal lesions [8] and its prognostic potential in
multiple myeloma [9] have been investigated. Despite these
results, quantitative DCE-MRI has never reached routine
clinical applications in bone imaging. The main reasons for
this might be the need for intravenous contrast administra-
tion, the suboptimal effectiveness of low-molecular-weight
contrast agents for a precise assessment of the marrow⁎ Corresponding author. Université Catholique de Louvain, Hôpital
Saint-Luc, Radiology–Imaging Unit, Avenue Hippocrate 10, 1200 Brussels,
Belgium. Tel.: +32 2 7642551; fax: +32 2 7705574.
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doi:10.1016/j.clinimag.2011.10.002microstructure [5,10], and the measurement of an arterial
input function. The computationally intensive postproces-
sing to get quantitative estimates of the bone marrow
microcirculation (including a precontrast mapping of T1 or a
calibration procedure, the modeling of the contrast agent
kinetics, and the implementation of a robust data fitting
procedure) is also involved. These requirements often lead to
choosing the simplest analysis model over more realistic
tracer kinetic models. However, as qualitative or semiquan-
titative models of bone marrow perfusion have never been
formally validated [5], more sophisticated models should not
be excluded from the process of model selection.
The aim of the study is to estimate the efficiency of the
current standard DCE-MRI postprocessing techniques to
assess bone marrow microcirculation. Qualitative analysis of
signal intensity vs. time (SI) curves, region of interest (ROI)-
based semiquantitative analysis, ROI-based kinetic modeling,
pixel-based kinetic modeling, and kinetic parameters-based
clustering were assessed on the basis of two populations:
patients with untreated bone metastases of PCa and control
patients with normal bone marrow. Reference values of bone
marrow perfusion, blood volume, and interstitial volume for
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represent baseline information for further studies focused on
perfusion changes in bonemetastases of PCa during treatment.
2. Materials and methods
2.1. Patients
Ten patients with bone metastases of PCa and 10 control
patients without history of cancer were included in the study
and underwent an MRI examination. Patients with bone
metastases of PCa had newly diagnosed PCa (mean age, 68
±9 years; range 52–80 years) referred by the oncology and/or
urology department to rule out bone metastases of the spine.
In all 10 patients, the MRI examination including DCE-MRI
was performed before any drug or radiation therapy was
started. Because of the lack of histological proof, a 6-month
follow-up by standard MRI survey for bone marrow was
used as a gold standard for the confirmation of the malignant
nature of the lesions considered as metastases and the
stability of bone marrow considered as normal. In this 6-
month interval, patients with PCa received hormonal
therapy, and bone metastases were proved by any change
of size and/or signal of the lesion over this time period (see
Table 1). Control patients without history of PCa underwent
MRI of the lumbar spine with contrast injection. All patients
were referred for a low-back-pain MRI workup by an
academic orthopedist. Patients with known disease that
could potentially alter bone marrow changes were discarded
from the analysis. These were patients with history of cancer
even without evidence/history of bone metastases, with
previous surgery of the lumbar spine, with chronic anemia
(defined as hemoglobin level b12 g ml−1), or with chronic
inflammatory disease (defined as reactive C-protein N1.5 mg
dL−1 and/or white blood cells N10,000 ml−1). All laboratory
tests were performed during the week before the MRI
examination. The final control population consisted of eight
patients, three men and five women (mean age, 56±14 years;
range 39–75 years) with normal bone marrow according toTable 1







1 80 8 b0.1
2 67 8 1470
3 55 9 3
4 74 6 11
5 70 6 1069
6 52 7 1369
7 74 7 115
8 69 9 202
9 65 7 3
10 56 7 144
PSA, Prostate-Specific Antigen.
a Sample lesion for DCE-MRI.
b Vertebral body considered as sample lesion: diffuse infiltration of bone mathe above-mentioned criteria. The study was approved by the
local ethical committee, and written informed consent was
obtained from patients.
2.2. Magnetic resonance standard imaging
All MRI examinations were performed on a 1.5-T scanner
(Gyroscan NT Intera 1.5 T; Philips Medical Systems, Best,
the Netherlands) with the body coil. For each patient, a
preliminary standard magnetic resonance examination of the
spine was performed using T1 and proton density with fat
saturation (PDFS) sequences (sagittal plane). Transverse
sections were then programed on bone metastases identified
on their preliminary images to delineate these lesions.
Control patients referred for back pain were also examined
with transverse T1 and T2 images obtained on the anatomic
levels relevant to the clinical question. Bone metastases were
defined as an area of low signal intensity on T1-weighted
images compared to normal muscle and/or disk and
intermediate to high signal intensity on the PDFS images.
2.3. DCE-MRI examination
Bone marrow perfusion was assessed with a spoiled two-
dimensional turbo-Fast Low Angle SHot sequence. A nonslice-
selective 90° preparation pulse was incorporated. Scan
parameters were as follows: slice thickness L=10 mm, Field
Of View=262×400 mm, in-plane voxel size=1.02×1.56 mm
after reconstruction, flip angle=15°, single shot, echo time=1.3
ms, repetition time=5.4 ms, a shot duration of 516 ms, and 200
dynamics for a total acquisition time of 1 min 47 s. Patients
received 8 ml of Gd-DTPA (Magnevist; Bayer Schering
Pharma AG, Berlin, Germany) followed by 20 ml saline flush
injected at a rate of 3 ml/s with an automated injector.
A single transverse slice that included bone metastases
or normal bonemarrow and the aortawas continuously scanned
using the fast-gradient echo sequence after contrast agent
injection. This single transverse slice was manually positioned
passing through the largest metastasis detected at the level ofTotal no. of lesions Location of the
largest lesion a













310 N. Michoux et al. / Clinical Imaging 36 (2012) 308–315the spine on the basis of sagittal slices. In control patients, the
single slice was positioned at level of the upper third of the L3
vertebral body to avoid the basivertebral veins and the cortex of
vertebral plates. The upper third of L3 vertebral body was
chosen because mechanic degenerative changes of bone
marrow are by far less common than in L4 and L5.
2.4. Image postprocessing
The software Image J (National Institutes of Health,
http://rsbweb.nih.gov/ij/) was used for the segmentation of
the ROIs. An experienced musculoskeletal radiologist
manually drew one ROI covering the aorta and another
ROI in the bone marrow. For bone metastasis, a careful
delineation of the lesion on the basis of sagittal and axial
images obtained before contrast agent injection was
performed. For normal marrow, the entire vertebral body
(except for the cortices) on the axial image was included in
the ROI. The program reported the ROI for each image of the
time series and extracted the SI curves.
2.5. Semiquantitative parameters
Bone marrow perfusion was first assessed using three
simple geometrical measurements of the signal intensity
enhancement [11]. The percentage increase (PI) in signal
intensity was calculated as follows:




= SIP pre ð1Þ
where SIΣpre is the mean signal intensity measurement in the
ROI before contrast agent arrival and SImax is the maximum
signal intensity measurement in the ROI during the first pass
of the contrast agent. The upslope was calculated by linear
regression of the signal intensity on the interval [SIpre;
SImax], where SIpre is the signal intensity measurement
measured just before the contrast agent uptake. The time
Tmax corresponding to the peak SImax was also measured.
2.6. Kinetic parameters
According to the procedure described in Ref. [12], SI
curves were converted into longitudinal relaxation rate R1
vs. time curves. A linear relationship was assumed between
R1 and contrast agent concentration according to the
following equation:
R1 = R1post − R1pre = r1C ð2Þ
where R1post is the postcontrast longitudinal relaxation rate,
R1pre the precontrast longitudinal relaxation rate, r1 the
longitudinal relaxivity of the contrast agent, and C is
concentration. In this equation, it is assumed that the
relaxivity of the contrast agent is the same in blood and
tumors and that the exchanges of water between intravas-
cular, extravascular, and intracellular spaces are fast [13].The extended Kety model with an individual arterial input
function was used [14,15]. This model assumes a bidirec-
tional exchange between two compartments, the intravascu-
lar space (IVS) and the extravascular extracellular space
(EES), as well as a contribution of the tracer in IVS. It can be
written as:
Ctissue tð Þ = q:K trans:Cplasma tð Þ  e−qK
trans
ve
t + vp:Cplasma tð Þ ð3Þ
where ρ (ρ=1 g ml−1) is the tissue density, Cplasma (g ml
−1) is
the concentration of contrast agent in IVS, Ctissue (g ml
−1) is
the concentration of contrast agent in the tissue, K trans=E·F
(ml s−1 g−1) is the product of the extraction fraction and
the tissue plasma flow, ve (%) is the EES accessible to the
contrast agent, vp (%) is the fractional plasma volume of
the contrast agent, and ⊗ denotes the convolution product.
The model contains three free parameters to fit,K trans, ve, and
vp. The hematocrit Hct was fixed to 0.45 for all patients, and
the arterial concentration of the tracer in whole blood was
converted into the corresponding plasma quantity according
to the following formula Cplasma(t)=Cblood(t)/(1−Hct).
For each patient, the kinetic model was first fitted to the
average R1 curve from the ROI. Then, it was fitted on a
pixel-by-pixel basis in the entire bone marrow of the vertebra
to generate three parametric maps based on K trans, ve, and vp.
To obtain the coefficient K trans (in ml min−1 100 g−1),
the coefficient expressed (in ml s−1 g−1) was multiplied
by 60 s min−1 and by 100.
A statistical partitioning of the pixels in bone marrow
based on the kinetic parameters was computed. Then, bone
metastases margins manually drawn by the radiologist on
the basis of T1-weighted imaging on precontrast T1 axial
images were compared to the map generated with the
clustering method.
2.7. Statistical analysis
Optimization of the fits was achieved with a weighted
nonlinear least squares procedure based on the Levenberg–
Marquardt method combined with a three-dimensional grid
of starting parameter values to find the solution correspond-
ing to the true global minimum of the error function [16].
The k-means clustering [17] approach, used to partition
the pixels in the bone marrow area, was parameterized with a
number of final clusters equal to 2, a preliminary clustering
phase on a random 10% subsample of the pixels and with the
L1 distance to calculate the distance between centroid
clusters. Pixels belonging to one cluster and showing a
distance measure to another cluster less than 0.5 were
considered as poorly classified.
Semiquantitative and kinetic parameters were expressed
as mean±S.D. Patients' age and parameters were compared
between both groups with the Wilcoxon rank sum test. A
P value of .05 was considered statistically significant. The
performance of the various parameters in discriminating the
normal bone marrow vs. the metastatic bone marrow was
Table 2
Mean values (±S.D.) of the semiquantitative and kinetic parameters




PCa 1.59±0.57 72±19 28±5 57.7±22.8 12.7±4.17 1.68±1.25
Control 0.47±0.27 19±10 33±8 18.6±11.9 4.78±1.59 1.00±0.01
Upslope in arbitrary unit·s−1, PI in %, Tmax in s, K
trans and kep in ml min
−1
100 g−1, and ve, and vp in %.
a Significant differences between metastatic and normal bone marrow
(Wilcoxon rank sum test, Pb.05).
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teristic (ROC) curves. Cutoff values for PI, upslope, K trans,
and ve as well as the corresponding sensitivity and specificity
were computed with exact 95% confidence intervals based
on the F distribution [18]. As the area under the ROC curve
(AUC) is a summary measure of the parameter performance,
we performed an unpaired statistical comparison of the
AUCs. All calculations were done with Matlab (v. 6.5, rel.
13; MathWorks, Natick, MA, USA).3. Results
Patients age did not differ between the controls and the
PCa patients (P=.39). Typical SI curves are presented in
Fig. 1. In the control patients, an almost flat profile is
observed. In bone metastases, the patients exhibited
different profiles with as common feature, a fast contrast
uptake and either a plateau or a rapid washout, but with an
intensity enhancement always much higher to that observed
in normal bone marrow. SI curves measured from two ROIs
placed in normal and a tumoral area of the same patient
with bone metastases revealed similar differences, with a
lower and slower intensity enhancement in the normal-
appearing area of the bone marrow.
Measurements of the semiquantitative and kinetic param-
eters are summarized in Table 2. Bone metastases showed a
significantly higher upslope compared to normal bone
marrow (P=.0002) as well as a significantly higher PI
(P=.00005). No statistically significant difference was found
in the time-to-peak Tmax between both groups (P=.26). Bone
metastases showed a significantly higher value of K trans, ve,
and vp compared to normal bone marrow (P=.0015,
P=.00004, and P=.0048, respectively).
The best estimated parameters used to predict the bone
marrow status were as follows: PI (AUC=1.00±0.00), ve
(AUC=0.99±0.03), upslope (AUC=0.97±0.05), and K transFig. 1. Example of observed SI curves. The mean signal intensity before the contras
bone marrow: the two lower black curves correspond to male patients, while the two
to the area of normal bone marrow next to the lesion in a metastatic patient (Fig.
demonstrate a higher and faster enhancement. The blue curve corresponds to the(AUC=0.96±0.05). The most discriminating cutoff values
were PIb38.02% (sensitivity, 100%; specificity, 100%),
veb7.41 % (sensitivity, 100%; specificity 90%),
upslopeb0.92 AU·s−1 (sensitivity, 100%; specificity, 90%),
and K transb35.73 ml min−1 100 g−1 (sensitivity, 100%;
specificity, 90%) for the normal bone marrow. A pairwise
comparison of AUC of ROC curves did not yield any
statistically significant differences. As a result, it was not
possible to distinguish the above parameters according to
their performance.
Parametric maps are illustrated in Fig. 2. In normal bone
marrow, a homogeneous distribution of low K trans, ve, and
vp values was typically observed. In bone metastases,
parametric maps vary among patients. Distributions of
K trans, ve, and vp values are heterogeneous, revealing several
functionally different areas in the bone marrow.
Clustering based on K trans and ve provided maps with the
lower number of pixels poorly classified compared to other
combinations of two or three parameters including vp.
Examples of clustering maps are presented in Fig. 3. In the
control patients, the partitioning typically results in a single
large area that is consistent with a manual delineation
covering the entire bone marrow of the vertebra in the axial
plane. In bone metastases, an overall good agreement was
observed between the area of the lesion delineated manually
and the area identified by the partitioning as an area wheret agent injection has been recentered on zero for a better comparison. Normal
upper black curves correspond to female patients. The red curve corresponds
2C, nonenhancing area). Untreated bone metastases: the four black curves
tumoral area in the second metastatic patient (Fig. 2C, enhancing area).
Fig. 2. Parametric maps of bone marrow perfusion. The brighter the color code, the higher the value of the functional parameter. (A) A control patient is shown.
Maps do not show any local difference. Dark areas representing hypoperfused areas with both small vascular and interstitial volumes are small, sparse,
colocalized from one map to the other, and witnesses for an overall low perfusion of the marrow. (B–D) Patients with untreated bone metastases are shown. High
values of the transfer constant Ktrans, interstitial volume ve, and plasma volume vp are observed. Maps are heterogeneous. (B) One observes that nonenhancing
areas cannot be colocalized from one map to the other, which witnesses for the complex characteristics of the metastatic marrow microstructure. (C) Two
functionally different areas are present: the nonenhancing area with low perfusion/permeability and moderate interstitial and vascular volumes appearing as
normal bone marrow, and the enhancing area with high perfusion/permeability and moderate interstitial and vascular volumes appearing as metastatic marrow.
312 N. Michoux et al. / Clinical Imaging 36 (2012) 308–315K trans values are higher. Substantial differences between
both methods of delineation can also be observed.4. Discussion
The main results of the study are as follows. ROI-based
semiquantitative and quantitative methodologies provide
clear cutoff values for the perfusion parameters, from
which bone metastases of PCa can be distinguished from
normal bone marrow. Both methodologies show that the
perfusion in normal bone marrow is lower compared to
that in bone metastases of PCa. Parametric maps based on
K trans, ve, and vp allow for the characterization of the
heterogeneity of bone metastasis. Clustering analysisallows for the segmentation of the lesion based on its
measured functional characteristics.4.1. Qualitative, semiquantitative, and
quantitative methodology
Qualitative analysis showed that SI curves in patients with
bone metastasis are mainly characterized by a marked
intensity enhancement. However, various patterns for the
washout phase can be observed and are difficult to classify.
Analysis of SI patterns has been applied with success to the
detection and evaluation of breast cancer [19]. Chen and
Shih [11] proposed a classification, more subjective than
strict, of SI patterns in patients with compression fracture or
Fig. 3. Sagittal T1-weighted images showing the transverse plan (yellow line) selected for the perfusion sequence, manual ROIs, and clustering maps
superimposed on the first image of the perfusion sequence before contrast agent injection. The statistical partitioning of the pixels is estimated from the functional
parameters Ktrans and ve. The pixel group with the lower mean K
trans value is coded in blue, while the pixels group with the higher mean Ktrans value is coded in
green. Pixels in red correspond to a poor classification result. Same patients as in Fig. 2 are presented. (A) A control patient is shown. The clustering results in one
type of tissue only. (B–D) Patients with untreated bone metastases are shown. The clustering reveals two distinct areas, especially in patients B and C, suggesting
two distinct types of tissue in the bone marrow. Pixels with a poor classification result are mainly localized on the border of both areas.
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analysis of SI patterns remains not very specific and is
mainly useful for detecting an abrupt change in the bone
marrow perfusion.
Values reported in the literature for semiquantitative
parameters vary greatly [11,20,21]. In our study, PI ranged
between 10% and 29% for the control patients and between
53% and 91% for patients with PCa. This result is consistent
with Baur et al. [22], who suggested that a PI less 40% is
observed in normal bone marrow of adults older than 30
years. Likewise, our values for the upslope ranged between
0.20 and 0.74 for the control patients and between 1.02 and
2.16 for patients with PCa, which is consistent with the
results of Montazel et al. [20] in patients with newly
diagnosed hematologic malignancies. In another study [23],
the same team showed that PI and upslope increased
significantly with the degree of bone marrow involvement.
Parameters K trans, ve, and vp were significantly lower in
normal bone marrow than in bone metastases. Few data inthe literature are available for comparison. Hillengass et al.
[9], using the model of Brix et al. [24], reported that high
values of parameters amplitude A (similar to our parameter
PI) and exchange rate kep indicated diffuse or focal
infiltration of the bone marrow. Our study yielded kep
values 375±173 ml min−1 100 g−1 in the control patients
and 478±214 ml min−1 100 g−1 in patients with bone
metastasis, similarly to the findings of Hillengass et al.
(where kep ranged from 0 to 798 ml min
−1 100 g−1). We
did not observe any significant difference in kep values
between the controls and the metastatic patients, but the role
of a particular kinetic parameter as diagnostic variable may
depend on the studied pathology.
4.2. Comparison of the methodologies
Similar performance, as well as substantial correlations
between the parameters (r≥0.7, data not shown), was found
between semiquantitative and quantitative methodology.
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the interval [SIpre; SImax]. Interval limits are sensitive to
signal-to-noise ratio and may result from a subjective
choice when the contrast agent uptake and washout are both
slow, which is the case in normal bone marrow. Moreover,
semiquantitative parameters are well known to be depen-
dent on MRI protocols (magnetic field, coils, and sequence
parameters) and baseline T1 relaxation time of the tissue
before contrast injection. Recently, a series of curves
features (defined from areas measurement under SI curves
normalized to account for both baseline signal intensity and
signal intensity 3 min after contrast agent injection) have
been presented as insensitive to T1 value and protocol
parameters [25]. However, first assessment in patients with
osteosarcoma showed only a weak correlation with the
transfer constant K trans.
Kinetic modeling requires an accurate determination of the
arterial input function (AIF) [26] and baseline T1 value.
Kinetic parameters have a clear physiological meaning,
though simplified regarding actual transport mechanisms
[27,28]. The extended Kety model has been reported as a
compromise between the Kety model, neglecting the vascular
contribution of the contrast agent, and the more physiological
(and more complex) St Lawrence and Lee model, giving more
accurate results but being also less precise because of the
interdependency of the parameters and their sensitivity to
initial values [29]. A recent study [30] suggested that kinetic
models should explicitly incorporate a fraction of fat (as an
additional parameter to be fitted or assume not fat because of
using a perfect fact saturation radio frequency pulse) to get
unbiased measurements of the bone marrow perfusion.
4.3. Pixel-wise quantitative methodology
Heterogeneity of tumoral perfusion may bias the
interpretation of ROI-based parameters [31]. Our results
confirm that fact, showing that the spatial distribution of
K trans, ve, and vp values is heterogeneous in bone metastases,
while it is not in normal bone marrow. Therefore, the mean
perfusion parameters are significant in normal bone marrow
only. Beside, pixel-based methodologies may allow for the
monitoring of the effects of vascular-targeting agents on each
perfusion parameter in the area of the lesion, in its immediate
vicinity, and in more distant locations [32]. To test this
hypothesis, we performed a short study on 10 PCa patients
with known lumbar metastases scheduled to receive
hormonal therapy or Taxotere (Sanofi-Aventis) therapy.
These patients were imaged within 1 week before and 7 and
90 days after initial treatment. Our results showed that K trans,
ve, and vp maps were sensitive to treatment changes and
allowed for the monitoring of the complex changes occurring
in the perfusion in response to therapy [33].
Clustering based on the kinetic parameters allows for the
identification of regions with similar functional characteris-
tics within the bone marrow. Our results show that in the
control patients, the bone marrow cannot be partitioned. Inpatients with bone metastasis, the marrow of the involved
vertebra is partitioned into two distinct regions: the lesion
(identified a posteriori by comparison with a manual
delineation), where K trans is high, and the normal-appearing
perilesional tissues, where K trans is low. Interestingly, the
clustering maps result in a more detailed segmentation of the
lesion compared to the margins of the bone metastases drawn
on the basis of T1-weighted imaging. We can speculate that
DCE-MRI may reveal areas of subtle bone marrow
infiltration at margins of the lesion in territories appearing
normal on standard T1-weighted sequences as previously
demonstrated in myeloma [22]. Similar statistical approaches
of DCE-MRI data already proved to be useful in detecting
and delineating the tumor (which, by extension, allows for
the quantitative measurement of the extension or the
shrinkage of the tumor between two examinations) and
grading its aggressiveness [34].
4.4. Limitations
The population we enrolled in this study was limited to 10
patients because we focused our analysis on newly
diagnosed untreated bone metastases of PCa to provide
baseline values of perfusion, without biases induced by
previous drug therapy. The control population included five
women. Several previous articles reported a significant
higher perfusion of bone marrow in younger patients,
especially in women in fertile age [22]. This may, however,
be considered as particularly suitable to determine a series of
cutoff values of perfusion between normal bone marrow and
bone metastases of PCa.
For each patient, we only studied the larger metastasis in
order to obtain the largest ROI and the highest signal-to-
noise ratio to fit the curve of enhancement. We deliberately
avoided to simultaneously image more than one metastases,
which would have been possible by orientating the single
slice on sagittal plane, parallel to the spine. An axial plane
focuses the analysis to single-bone metastases but also
provides a measurement of the AIF that is less prone to flow
and pulsation artifacts as well as to partial volume effects. As
bone metastases represent a heterogeneous population of
malignant lesions, we are aware that the choice of a lesion as
a sample to monitor the response to drug therapy would be
purely arbitrary in clinical settings.
In conclusion, pixel-wise kinetic modeling should
constitute the reference methodology to assess bone marrow
microcirculation. The information provided by kinetic
parameters regarding the tumoral processes affecting the
bone marrow microcirculation justifies the additional cost in
data postprocessing. Especially, the measurement of an
arterial input function is no more a limiting factor since
alternative methods of AIF generation are currently
investigated [35] and may offer the possibility of acquiring
images with a higher spatial resolution and/or signal-to-noise
ratio, as well as performing accurate kinetic modeling of
DCE-MRI data in the whole spine. Future investigations
315N. Michoux et al. / Clinical Imaging 36 (2012) 308–315should focus on the relevance of K trans, ve, and vp maps as
imaging biomarkers in the treatment monitoring and
follow-up of bone metastases of PCa treated by anti-
angiogenetic/cytotoxic drugs.
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